Proteins whose transcriptional control is disabled upon BET inhibition in MPN model cells include, in addition to c-Myc, PIM1 and BCL-xL (notably, two therapeutic targets described in this review), among others [107,108,110]. Here, PIM1 is linked to myeloproliferative disorder.